Anna Vilgelm

5PUBLICATIONS
22CO-AUTHORS
Molecular targetsCardiology (incl. cardiovascular diseases)Cancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Jul 22, 2026
Therapy-induced senescence rewires the melanoma secretome to promote antitumor immune response and augment cell therapies.

|Nov 21, 2023
Synergistic Role of NK Cells and Monocytes in Promoting Atherogenesis in Severe COVID-19 Patients.

Manuja Gunasena, Mario Alles, Yasasvi Wijewantha

|Jul 29, 2023
Generation of Orthotopic Patient-Derived Xenografts in Humanized Mice for Evaluation of Emerging Targeted Therapies and Immunotherapy Combinations for Melanoma.

Chi Yan, Caroline A Nebhan, Nabil Saleh

|May 25, 2023
Dendritic cell therapy augments antitumor immunity triggered by CDK4/6 inhibition and immune checkpoint blockade by unleashing systemic CD4 T-cell responses.

Amrendra Kumar, Vijay Ramani, Vijaya Bharti

|Aug 16, 2019
MDM2 antagonists overcome intrinsic resistance to CDK4/6 inhibition by inducing p21.

Anna E Vilgelm, Nabil Saleh, Rebecca Shattuck-Brandt

Pageof 1

Frequent Collaborators

2 joint publications

Ann Richmond

1 joint publications

Rebecca Shattuck-Brandt

1 joint publications

Sheau-Chiann Chen

1 joint publications

C Andrew Johnson